Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 20;14(4):93461. doi: 10.5662/wjm.v14.i4.93461

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Role of personalized medicine and molecular imaging in colorectal cancers. The function and role of molecular imaging and personalized medicine in charge of management of colorectal cancers is shown schematically in the picture, and the possibility of playing the role of these two concepts does not have any special priority or delay and can be simultaneous and parallel. The role of these two concepts is to adopt the most accurate, appropriate, and personalized mode for patients with colorectal cancers, including the basic steps of collecting individual demographic information of patients, collecting human samples, including blood, urine, and biopsy samples etc, and examination and analysis, screening, in the diagnostic path using common and novel imaging and anatomical laboratory methods and even at the cellular and molecular level, determining the most suitable and targeted treatment method including various medical methods (drugs, type and amount), and types of surgical methods, radiation therapy or combined methods, determining the rate of response to treatment, recurrence, prognosis and follow-up of patients according to the characteristics of each patient. Imaging modalities including positron emission tomography (PET), 18F-fluorodeoxyglucose (FDG) PET, FDG-PETPET, 68[Ga]Ga-DOTA-fibroblast activation protein inhibitor (FAPI)-04 PET/computed tomography (CT), 68Ga-FAPI PET/CT, magnetic resonance imaging (MRI), including dynamic contrast-enhanced imaging (DCE) MRI and CT perfusion imaging in determining the course diagnosis, prognosis and FDG-PET/CT, 18F-FDG PET/CT, 68Ga-FAPI PET/CT, and DCE-MRI in treatment.